[go: up one dir, main page]

CY1109994T1 - Βελτιωμενο σχεδιο συνθεσης για τη λακοσαμιδη - Google Patents

Βελτιωμενο σχεδιο συνθεσης για τη λακοσαμιδη

Info

Publication number
CY1109994T1
CY1109994T1 CY20101100383T CY101100383T CY1109994T1 CY 1109994 T1 CY1109994 T1 CY 1109994T1 CY 20101100383 T CY20101100383 T CY 20101100383T CY 101100383 T CY101100383 T CY 101100383T CY 1109994 T1 CY1109994 T1 CY 1109994T1
Authority
CY
Cyprus
Prior art keywords
lacosamidi
improved composition
composition plan
compound
formula
Prior art date
Application number
CY20101100383T
Other languages
English (en)
Inventor
Jens Riedner
Gavin Dunne
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CY1109994T1 publication Critical patent/CY1109994T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μια βελτιωμένη μέθοδο παραγωγής (R)-2-ακεταμιδο-Ν-βενζυλο-3-μεθοξυπροπιοναμιδίου (λακοσαμίδης) που περιλαμβάνει την Ο-μεθυλίωση μιας ένωσης του τύπου (Ι) για την παραγωγή μιας ένωσης του τύπου (ΙΙ) σε αντίδραση ενός βήματος.
CY20101100383T 2004-10-02 2010-04-30 Βελτιωμενο σχεδιο συνθεσης για τη λακοσαμιδη CY1109994T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023556A EP1642889A1 (en) 2004-10-02 2004-10-02 Improved synthesis scheme for lacosamide
EP05794396A EP1799635B1 (en) 2004-10-02 2005-09-30 Improved synthesis scheme for lacosamide

Publications (1)

Publication Number Publication Date
CY1109994T1 true CY1109994T1 (el) 2014-09-10

Family

ID=34926827

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100383T CY1109994T1 (el) 2004-10-02 2010-04-30 Βελτιωμενο σχεδιο συνθεσης για τη λακοσαμιδη

Country Status (24)

Country Link
US (2) US7884134B2 (el)
EP (2) EP1642889A1 (el)
JP (1) JP5128281B2 (el)
KR (1) KR101246169B1 (el)
CN (2) CN101928230B (el)
AT (1) ATE457975T1 (el)
AU (1) AU2005291456B2 (el)
BR (1) BRPI0516735B8 (el)
CA (1) CA2570598C (el)
CY (1) CY1109994T1 (el)
DE (1) DE602005019437D1 (el)
DK (1) DK1799635T3 (el)
EA (1) EA012588B1 (el)
ES (1) ES2341470T3 (el)
HR (1) HRP20100239T1 (el)
IL (1) IL180479A (el)
MX (1) MX2007001253A (el)
NO (1) NO336765B1 (el)
NZ (1) NZ552076A (el)
PL (1) PL1799635T3 (el)
SI (1) SI1799635T1 (el)
UA (1) UA95600C2 (el)
WO (1) WO2006037574A1 (el)
ZA (1) ZA200610000B (el)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
CA2545543A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
AU2005232395B2 (en) * 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
JP2008510758A (ja) * 2004-08-27 2008-04-10 シュヴァルツ・ファーマ・アーゲー 骨肉腫の痛み、化学療法誘発性及びヌクレオシド誘発性の痛みを治療するためのペプチド化合物の新規使用
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
CN101484247A (zh) 2005-11-24 2009-07-15 克诺普拉斯技术股份公司 用流动性涂层材料为光滑的或具有构造结构的表面涂层的涂层设备
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US8093426B2 (en) 2007-12-04 2012-01-10 Ranbaxy Laboratories Limited Intermediate compounds and their use in preparation of lacosamide
EP2297092A1 (en) 2008-05-28 2011-03-23 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
MX2011004324A (es) * 2008-11-07 2011-09-21 Ucb Pharma Gmbh Proceso novedoso para la preparacion de derivados de aminoacidos.
DE102008059155A1 (de) 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
CN101591300B (zh) * 2009-02-19 2011-05-04 成都伊诺达博医药科技有限公司 合成拉考沙胺的新方法
WO2010107993A2 (en) 2009-03-18 2010-09-23 Pliva Hrvatska D.O.O. Process for preparing (r)-7v-benzyl-2- (benyloxycarbonylamino)-s-methoxypropionamide
WO2011015617A1 (en) * 2009-08-06 2011-02-10 Medichem, S.A. Solid forms of an n-(phenylmethyl)propanamide derivative and processes of preparation
CN102020589B (zh) * 2009-09-19 2013-11-06 浙江九洲药业股份有限公司 一种氨基甲酸叔丁酯衍生物及其制备方法和应用
WO2011039781A1 (en) 2009-09-25 2011-04-07 Cadila Healthcare Limited Processes for the preparation of lacosamide and intermediates thereof
US20130085304A1 (en) * 2009-11-19 2013-04-04 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
WO2011092672A2 (en) * 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Processes for reducing impurities in lacosamide
IT1398044B1 (it) * 2010-01-29 2013-02-07 Archimica Srl Processo per la preparazione della lacosamide
US8829226B2 (en) * 2010-02-06 2014-09-09 Zhejiang Jiuzhou Pharmaceutical Co., Ltd Lacosamide intermediate compound, preparation method thereof and use thereof
CN102146048B (zh) * 2010-02-06 2013-11-13 浙江九洲药业股份有限公司 拉科酰胺中间体化合物及其制备方法和应用
EP2534128A1 (en) 2010-02-08 2012-12-19 Natco Pharma Limited A process for the preparation of lacosamide
WO2011099033A1 (en) 2010-02-09 2011-08-18 Msn Laboratories Limited Process for preparing (r)-2-acetamido-n-benzyl-3-methoxy-propionamide
WO2011130615A2 (en) * 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
US20130123537A1 (en) * 2010-05-17 2013-05-16 K a s s Narayan Garimella Process for the preparation of lacosamide
WO2011158194A1 (en) 2010-06-15 2011-12-22 Medichem, S.A. Enzymatic resolution of racemic (2r,s)-2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide
EP2399901A1 (en) * 2010-06-23 2011-12-28 Archimica GmbH Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
US20130102811A1 (en) * 2010-07-02 2013-04-25 Sun Pharmaceutical Industries Ltd Process for the preparation of lacosamide
EP2598476B1 (en) 2010-07-27 2014-07-02 Indoco Remedies Limited Process for preparation of lacosamide and some n-benzyl-propanamide intermediate derivatives
EP2621893A1 (en) 2010-10-01 2013-08-07 UCB Pharma GmbH Process for the preparation of amino acid derivatives
HUE031138T2 (en) 2010-10-19 2017-06-28 Euticals Gmbh A method of producing lacosamide
EP2487152A1 (en) 2010-11-17 2012-08-15 UCB Pharma GmbH Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
GB201020026D0 (en) 2010-11-25 2011-01-12 Cambrex Karlskoga Ab New process
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN102320993B (zh) * 2011-07-13 2013-11-27 石家庄四药有限公司 一种制备(r)-2-叔丁氧羰基氨基-3-甲氧基丙酸的方法
WO2013024383A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited An improved process for the preparation of lacosamide
US9133101B2 (en) 2011-08-29 2015-09-15 Signa S.A. De C.V. Processes for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide and intermediates thereof
WO2013072933A2 (en) * 2011-10-03 2013-05-23 Glenmark Generics Limited Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
EP2776388A4 (en) 2011-11-10 2015-07-08 Davuluri Ramamohan Rao AN INEDIC PROCESS FOR THE PREPARATION OF (R) -N-BENZYL-2-ACETAMIDO-3-METHOXYPROPIONAMIDE
EA024260B8 (ru) 2011-11-15 2016-11-30 Санофи-Авентис Дойчланд Гмбх Способ получения n-замещенных 2-(ацетамино)-n'-бензил-3-метоксипропанамидов
US8748660B2 (en) 2012-07-09 2014-06-10 Council Of Scientific & Industrial Research Process for the synthesis of antiepileptic drug lacosamide
CN102816083B (zh) * 2012-07-30 2015-09-23 永光制药有限公司 拉科酰胺的制备方法
GB201219627D0 (en) 2012-11-01 2012-12-12 Cambrex Karlskoga Ab New process
WO2014155264A1 (en) 2013-03-25 2014-10-02 Jubilant Life Sciences Limited Process for the preparation of lacosamide using novel intermediates
CN103342655A (zh) * 2013-07-02 2013-10-09 扬州大学 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法
KR101578979B1 (ko) 2013-11-08 2015-12-18 에스티팜 주식회사 라코사마이드의 제조방법
AU2015308035B2 (en) 2014-08-28 2019-04-04 RAO, Davuluri Ramamohan Improved process for the preparation of Lacosamide and its novel intermediate
JPWO2016039393A1 (ja) * 2014-09-10 2017-06-22 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN104761465B (zh) * 2015-03-18 2017-05-31 四川同晟生物医药有限公司 一种拉科酰胺的制备方法
CN106699595B (zh) * 2015-07-21 2019-04-12 上海医药集团股份有限公司 一种拉科酰胺制备方法
CN106699605B (zh) * 2015-07-21 2019-08-20 上海医药集团股份有限公司 一种拉科酰胺中间体的甲基化方法
IN2015CH05001A (el) 2015-09-18 2015-10-16 Divis Lab Ltd
JP6905937B2 (ja) 2015-11-13 2021-07-21 株式会社エーピーアイ コーポレーション ラコサミド及びその中間体の製造方法
MX2018008021A (es) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
US9718765B1 (en) 2016-06-21 2017-08-01 Sci Pharmtech, Inc. Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives
SI3519382T1 (sl) * 2016-09-28 2022-02-28 Unichem Laboratories Ltd. Izboljšan postopek za pripravo lakozamida
CN106811492B (zh) * 2017-01-18 2019-11-01 长兴制药股份有限公司 一种拉科酰胺的制备方法
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081386A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN110320291A (zh) * 2019-06-21 2019-10-11 山东省药学科学院 一种hplc法定量检测拉考沙胺注射液含量的方法
JP2022072636A (ja) * 2020-10-30 2022-05-17 住友化学株式会社 アミド化合物の製造方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5129456A (en) * 1974-08-30 1976-03-12 Tanabe Seiyaku Co Kogakukatsusei oo benjiruserinjudotai no seiho
JPS62132849A (ja) * 1985-12-04 1987-06-16 Toray Ind Inc Ｄ−またはＬ−Ｎ−ｔ−ブトキシカルボニル−Ｏ−ベンジルセリンの製造方法
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
ES2157567T3 (es) * 1996-03-15 2001-08-16 Res Corp Technologies Inc Derivados de aminoacidos enantiomericos que tienen efecto anticonvulsivo.
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
JP3996671B2 (ja) * 1997-07-09 2007-10-24 タマ化学工業株式会社 Ｎ−アルコキシカルボニル化、ｎ−アルケニルオキシカルボニル化またはｎ−アリールアルコキシカルボニル化されたアミノ酸類の製造方法
CZ2004362A3 (cs) * 2000-08-17 2005-01-12 Teva Pharmaceutical Industries Ltd. Použití derivátů amidů kyseliny valproové a amidů kyseliny 2-valproenové pro léčbu nebo prevenci bolesti a/nebo bolesti hlavy
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
WO2004014895A1 (en) * 2002-08-05 2004-02-19 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
CA2545543A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
AU2005232395B2 (en) * 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
JP2008510758A (ja) * 2004-08-27 2008-04-10 シュヴァルツ・ファーマ・アーゲー 骨肉腫の痛み、化学療法誘発性及びヌクレオシド誘発性の痛みを治療するためのペプチド化合物の新規使用
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
AU2007260207B2 (en) * 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20130251813A1 (en) * 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide

Also Published As

Publication number Publication date
EP1799635A1 (en) 2007-06-27
IL180479A (en) 2011-09-27
AU2005291456A1 (en) 2006-04-13
WO2006037574A1 (en) 2006-04-13
DK1799635T3 (da) 2010-05-17
US7884134B2 (en) 2011-02-08
US20080027137A1 (en) 2008-01-31
UA95600C2 (en) 2011-08-25
IL180479A0 (en) 2007-06-03
ES2341470T3 (es) 2010-06-21
CN1989102B (zh) 2011-04-20
AU2005291456B2 (en) 2011-02-24
BRPI0516735B1 (pt) 2021-01-12
US8809585B2 (en) 2014-08-19
EA012588B1 (ru) 2009-10-30
DE602005019437D1 (el) 2010-04-01
PL1799635T3 (pl) 2010-10-29
BRPI0516735B8 (pt) 2021-05-25
US20110130350A1 (en) 2011-06-02
JP5128281B2 (ja) 2013-01-23
NO20072250L (no) 2007-04-30
KR101246169B1 (ko) 2013-03-21
MX2007001253A (es) 2008-10-02
HRP20100239T1 (hr) 2010-06-30
KR20070057778A (ko) 2007-06-07
CN101928230A (zh) 2010-12-29
NO336765B1 (no) 2015-10-26
CN1989102A (zh) 2007-06-27
SI1799635T1 (sl) 2010-06-30
CA2570598A1 (en) 2006-04-13
JP2008514669A (ja) 2008-05-08
CN101928230B (zh) 2012-11-07
NZ552076A (en) 2010-09-30
EP1799635B1 (en) 2010-02-17
BRPI0516735A (pt) 2008-09-23
ZA200610000B (en) 2007-08-29
EA200700746A1 (ru) 2007-08-31
EP1642889A1 (en) 2006-04-05
CA2570598C (en) 2013-12-17
ATE457975T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
CY1109994T1 (el) Βελτιωμενο σχεδιο συνθεσης για τη λακοσαμιδη
ATE480517T1 (de) Verfahren zur herstellung und reinigung von 2- hydrocarbyl-3,3-bis(4-hydroxyaryl-phthalimidin- monomeren
ATE556085T1 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
EA200701738A1 (ru) Способ получения транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
EA200870038A1 (ru) Способ получения аминов
ATE440815T1 (de) Verfahren zur herstellung von dialkylcarbonaten
ATE378312T1 (de) Verfahren zur herstellung von adapalene
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
ATE513801T1 (de) Verfahren zur synthese von propargylatierten aminoindanderivativen
TW200612959A (en) Method for preparing hydroxamic acids
AR056805A1 (es) Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
BR0214445A (pt) Processos para produzir compostos e composto
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
BRPI0514975A (pt) processo para produzir trietanolamina, e, trietanolamina
ATE399757T1 (de) Neues verfahren zur herstellung von nitrooxyderivaten von paracetamol
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
EA200600542A1 (ru) Способ для производства thip
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA200700767A1 (ru) Способ получения пиразолов
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
SE0400410D0 (sv) New compounds
ATE469141T1 (de) Verfahren zur herstellung von substituierten thiophensulfonylisocyanaten